Trial Profile

A Phase 1, First-in-human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jul 2025 According to Vir Biotechnology media release, Dose escalation continues for this study of PRO-XTEN™ dual-masked TCEs VIR-5500 (PSMA), with compelling early clinical response signals and promising safety profiles.
07 May 2025 According to a Vir Biotechnology media release, company continues to advance through dose escalation aiming to further optimize dosing and efficacy.
08 Jan 2025 Preliminary safety and efficacy results (n=18) presented in the Vir Biotechnology Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com